

EHA2026 Congress

June 11–14, 2026
Stockholm, Sweden



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.

Thank you to the funders of the AML Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our current funders can be found at [AML-Hub.com](https://www.aml-hub.com).

EHA2026: Top abstracts in AML

June 11–14, 2026

Oral presentations: Thursday, June 11

Abstract	Title	Presenter	Time (CEST)
S126 View	Opti-AML: Prospective randomized phase 2 trial of 28 versus 14 day schedule of venetoclax and azacitidine for 2 cycles in newly diagnosed genomically agnostic acute myeloid leukemia patients ≥ 60 years	Uma Borate	17:00–17:15
S127 View	A multicenter phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib in <i>IDH1</i> -mutated acute myeloid leukemia (AML)	Jennifer Marvin-Peek	17:15–17:30
S128 View	Venetoclax and azacitidine for molecular failure intervention as a bridge-to-transplant strategy for <i>NPM1</i> -mutated acute myeloid leukemia: The GIMEMA AML2521 phase 2 trial	Chiara Sartor	17:30–17:45
S129 View	Prospective NAMLG LD-VenEx trial: Azacitidine in combination with reduced duration of venetoclax in patients with <i>de novo</i> , secondary, and relapsed/refractory acute myeloid leukemia	Anne Louise Tølbøll Sørensen	17:45–18:00
S136 View	Impact of two versus three chemotherapy cycles before HSCT in MRD-negative pediatric AML: A multicenter retrospective study	Lindsey Murphy	17:00–17:15

Oral presentations: Friday, June 12

Abstract	Title	Presenter	Time (CEST)
S170 View	CPX-351 versus standard of care as bridging to alloHCT in patients with higher-risk myelodysplastic neoplasms or oligoblastic acute myeloid leukemia: Results of the randomized phase 2 PALOMA study	Uwe Platzbecker	17:15–17:30
S327 View	Prognostic importance of pre-treatment health-related quality of life and fitness indicators in older adults with acute myeloid leukemia. Analysis from the international EORTC AML 21 phase 3 trial	Fabio Efficace	17:45–18:00

Oral presentations: Saturday, June 13

Abstract	Title	Presenter	Time (CEST)
LB5007 View	First-in-class switchable allogeneic CAR-T therapy for CD123+ AML – Results from the phase IA REVSTAR-123 (AVC-201-01) study	Martin Wermke	13:15–13:30
S260 View	Integrated metabolic and epigenetic profiling uncovers distinct immune-escape programs and targetable vulnerabilities in post-transplant AML relapse	Annalisa Tamani	17:15–17:30
S274 View	A genetic-clinical prognostic algorithm for risk stratification in patients with relapsed/refractory acute myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation	Yue Jin	18:15–18:30

Oral presentations: Sunday, June 14

Abstract	Title	Presenter	Time (CEST)
LB5005 View	Gilteritinib versus midostaurin in patients with newly diagnosed <i>FLT3</i> -mutated acute myeloid leukemia eligible for intensive therapy: Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial	Marc Raaijmaker	10:15–10:30
S130 View	Ziftomenib combined with intensive induction (7+3) for newly diagnosed <i>NPM1</i> -m or <i>KMT2A</i> -r acute myeloid leukemia (AML): Long-term results from the KOMET-007 trial	Amer M. Zeidan	11:00–11:15
S131 View	A phase II randomized study of AK117 versus placebo in combination with venetoclax and azacitidine in previously untreated acute myeloid leukemia patients ineligible for intensive chemotherapy	Huafeng Wang	11:15–11:30
S133 View	Intensive chemotherapy in combination with quizartinib versus midostaurin for <i>FLT3</i> -ITD mutated acute myeloid leukemia: A multicenter cohort study	Michelle Lee	11:45–12:00
S134 View	TUSCANY study of safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in study participants with newly diagnosed AML ineligible for induction chemotherapy	Nikolai Podoltsev	12:00–12:15

Posters

Abstract	Title	Presenter	Date and time (CEST)
PF489 View	Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in <i>KMT2A</i> , <i>NPM1</i> , or <i>NUP98</i> : Updated phase 1 results from SNDX-5613-0708	Ibrahim Aldoss	Friday, June 12, from 18:45
PF495 View	Phase 1/2 study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in relapsed/refractory AML	Branko Cuglievan	Friday, June 12, from 18:45
PF509 View	Triplet therapy with quizartinib, decitabine, and venetoclax in newly diagnosed and relapsed/refractory <i>FLT3</i> -ITD acute myeloid leukemia	Musa Yilmaz	Friday, June 12, from 18:45
PF514 View	Efficacy of revumenib in acute myeloid leukemia harboring <i>NPM1</i> -mutated co-mutations: Post hoc analysis of AUGMENT-101	James S. Blachly	Friday, June 12, from 18:45
PF521 View	Impact of prior induction cycle number on outcomes with gilteritinib in relapsed/refractory <i>FLT3</i> -mutated AML: A pooled post-hoc analysis of ADMIRAL and COMMODORE studies	Mark Levis	Friday, June 12, from 18:45
PF536 View	Real-world management practices with venetoclax-based therapy for AML - Results from the prospective REVIVE study	Yakir Moshe	Friday, June 12, from 18:45

Posters (continued)

Abstract	Title	Presenter	Date and time (CEST)
PF542 View	Revumenib in the real world: Interim findings from the ROAR study in relapsed/refractory acute leukemia	Shai Shimony	Friday, June 12, from 18:45
PF550 View	A phase I/II study of gilteritinib and momelotinib in adults with relapsed or refractory <i>FLT3</i> -mutated acute myeloid leukemia	Nicholas Short	Friday, June 12, from 18:45
PF555 View	No evidence of QTc interval prolongation with the menin inhibitor bleximenib when given as monotherapy or in combination with AML-directed therapies for <i>KMT2A</i> or <i>NPM1</i> altered AML	Maher Abdul-Hay	Friday, June 12, from 18:45
PS1512 View	Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: Results from the ALFA-1200 cohort	Augustin Boudry	Saturday, June 13, from 18:45
PS1599 View	ALIDHE: A phase 3b study assessing ivosidenib + azacitidine in adults with newly diagnosed <i>m/DH1</i> acute myeloid leukaemia who are ineligible for intensive induction chemotherapy	Paresh Vyas	Saturday, June 13, from 18:45
PS1607 View	Clinical activity of revumenib in patients with relapsed/refractory (R/R) <i>NUP98</i> -rearranged acute leukemias	Ghayas Issa	Saturday, June 13, from 18:45
PS1617 View	Real-world outcomes in <i>MECOM</i> -rearranged AML: The largest multicenter cohort reported to date	Cecilia Arana Yi	Saturday, June 13, from 18:45
PS1621 View	Phase I/phase 2 study of quizartinib combined with CLIA in newly diagnosed and relapsed/refractory <i>FLT3</i> -mutated and wild-type acute myeloid leukemia	Musa Yilmaz	Saturday, June 13, from 18:45
PS1627 View	Long-term follow up of oral decitabine/cedazuridine (ASTX727) plus venetoclax in newly diagnosed acute myeloid leukemia: A phase 2 study	Thura Win Htut	Saturday, June 13, from 18:45
PS1631 View	Revumenib therapy post hematopoietic stem cell transplant for patients with relapsed/refractory <i>KMT2Ar</i> , <i>NPM1m</i> , and <i>NUP98r</i> acute myeloid leukemia: Post hoc analysis of outcomes from AUGMENT-101	Andrius Žučenka	Saturday, June 13, from 18:45



#EHA2026

Follow us on X to keep up to date
with the latest from the congress

@AML_Hub



Brought to you by

